AKT1 and cancer: The mechanisms responsible for sorafenib resistance are complex, but includes the activation of epidermal growth factor receptor (EGFR), c-Jun and the Akt pathway, as well as increases in cancer stem cells, and enhancement of epithelial-mesenchymal transition (EMT) [11].